Mu GH, Li X, Lu ZQ, et al. - Researchers conducted a retrospective study to evaluate the usefulness of high-flow nasal cannula (HFNC) therapy in patients with chest trauma and identify the risk factors associated with treatment failure. Between June 2016 and March 2019, researchers distinguished 44 acute respiratory failure patients with chest trauma who received HFNC therapy at the Fourth Affiliated Hospital of Nantong University. Individuals were classified into success and failure groups according to their response to HFNC therapy. They retrospectively examined the medical records to distinguish useful risk factors for HFNC treatment failure. It was reported that in patients with chest trauma, HFNC therapy was safe and effective, and more than 50% of the patients successfully recovered from acute respiratory failure without invasive ventilation. For HFNC treatment failure, a high Thoracic Trauma Severity Score could be a significant risk factor and had a high predictive performance.